Revolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022. In the quarter to June 2026, EPS fell 133.6%, free cash flow fell 70.0% and total debt rose 322.7%, each against the same quarter a year earlier.
Follow RVMD
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Gross Profit |
+8 more TTM periods Free account |
— | — | — | — |
R&D Expenses |
879.91 | 987.33 | 1,125.55 | 1,296.34 | |
SG&A Expenses |
157.14 | 195.04 | 261.28 | 330.91 | |
Operating Income |
(1,037.05) | (1,182.37) | (1,386.83) | (1,627.25) | |
Non-operating Income/Expense |
75.32 | 51.07 | 15.13 | (141.04) | |
Non-operating Interest Expenses |
33.74 | 35.18 | 36.43 | 59.34 | |
| (961.73) | (1,131.30) | (1,371.70) | (1,768.28) | ||
Income after Tax |
(960.98) | (1,131.30) | (1,371.70) | (1,768.28) | |
Net Income Common |
(960.98) | (1,131.30) | (1,371.70) | (1,768.28) | |
EPS (Basic) |
(5.17) | (5.91) | (7.07) | (8.82) | |
EPS (Diluted) |
(5.17) | (5.91) | (7.07) | (8.82) | |
Shares (Basic, Weighted) |
183.42 | 189.02 | 191.51 | 197.09 | |
Shares (Diluted, Weighted) |
183.42 | 189.02 | 191.51 | 197.09 | |
EBIT Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
EBT margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
EBITDA |
(1,053.91) | (1,193.64) | (1,390.69) | (1,627.00) | |
EBIT |
(1,037.05) | (1,182.37) | (1,386.83) | (1,627.25) | |
EPS (Diluted, from Cont. Ops) |
(5.19) | (5.95) | (7.11) | (8.85) | |
EPS (Diluted, Consolidated) |
(5.19) | (5.95) | (7.11) | (8.85) | |
EPS (Basic, Consolidated) |
(5.19) | (5.95) | (7.11) | (8.85) | |
Shares (Diluted, Average) |
184.93 | 190.66 | 193.15 | 198.72 | |
EPS (Basic, from Continuous Ops) |
(5.19) | (5.95) | (7.11) | (8.85) | |
Income from Continuous Operations |
(960.98) | (1,131.30) | (1,371.70) | (1,768.28) | |
Consolidated Net Income/Loss |
(960.98) | (1,131.30) | (1,371.70) | (1,768.28) | |
EBITDA Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating Cash Flow Margin |
0.00% | 0.00% | 0.00% | 0.00% |